Researchers Develop Gene Signature to Predict Immunotherapy Response in Triple-Negative Breast Cancer
Key Insights
Researchers developed a 15-gene tumor immune microenvironment signature (TIME-GES) that successfully distinguishes between "hot" and "cold" tumors with over 80% accuracy, outperforming existing immune-related gene signatures.
Using TIME-GES for drug screening, scientists identified Nitidine Chloride (search) (NCD (search)) as a potential immunotherapeutic agent that enhances CD8 (search)+ T cell infiltration and suppresses tumor growth in triple-negative breast cancer (search) models.
The study demonstrates that NCD (search) works by targeting JAK2 (search) protein and inhibiting the JAK2-STAT3 (search) signaling pathway, leading to upregulation of immune-activating genes and improved anti-tumor immunity.
Scientists have developed a novel gene expression signature that could revolutionize immunotherapy selection for triple-negative breast cancer (search) (TNBC (search)), one of the most aggressive forms of breast cancer (search). The research, published in Frontiers in Immunology, introduces a 15-gene tumor immune microenvironment signature (TIME-GES) that accurately predicts which patients will respond to immunotherapy and identifies promising new treatment compounds.
Breaking Through the "Cold Tumor" Challenge
TNBC (search) represents approximately 10-20% of all breast cancers but accounts for a disproportionate number of cancer deaths due to its aggressive nature and limited treatment options. Unlike other breast cancer (search) subtypes, TNBC lacks estrogen, progesterone, and HER2 receptors, making targeted therapies ineffective. Most TNBC tumors are classified as immunologically "cold," meaning they have low levels of tumor-infiltrating lymphocytes (TILs) and respond poorly to immunotherapy.
The research team, led by investigators from multiple institutions, addressed this challenge by analyzing transcriptomic data from two independent patient cohorts: 144 lung adenocarcinoma (search) patients and 20 melanoma (search) patients treated with anti-PD-1 therapy. Through differential expression analysis, they identified 15 genes that were consistently upregulated in "hot" tumors and treatment responders.
Superior Predictive Performance
The TIME-GES demonstrated remarkable accuracy in distinguishing tumor immune phenotypes, achieving an area under the curve (AUC) greater than 0.8 with 71% overall accuracy. The signature showed precision and recall rates of 0.7 and 0.9, respectively, significantly outperforming six established tumor immune-related gene signatures and four widely used immune checkpoint blockade response biomarkers.
"TIME-GES outperformed existing signatures in identifying 'hot' tumors," the researchers reported. The 15-gene signature includes critical immune-related genes such as CCR5, CD3E, CD8B, CXCL10 (search), CXCL11, EBI3 (search), FLT3LG (search), GZMB, IFNG, and LAG3, among others.
Strong Correlation with Immune Activity
Analysis across 30 cancer types revealed that all 15 TIME-GES genes showed significant positive correlations with 14 immune cell subsets, including activated CD8 (search)+ T cells, effector memory CD8+ T cells, and various other immune populations. The strongest correlations were observed with T cell subsets, particularly activated and effector memory CD8+ T cells, with mean Pearson correlation coefficients exceeding 0.65.
In breast cancer (search) patients, the TIME-GES composite score demonstrated strong positive correlations with CD8 (search)+ T cell infiltration levels (R > 0.8, P < 0.001), underscoring the signature's ability to capture tumor immune status accurately.
Prognostic Value Across Cancer Types
The clinical utility of TIME-GES extends beyond prediction of immunotherapy response. In breast cancer (search) patients, high expression of 12 out of 15 genes (80%) was significantly associated with prolonged overall survival. Patients with high TIME-GES scores exhibited significantly improved outcomes across multiple survival metrics, including overall survival, progression-free interval, disease-specific survival, and disease-free interval.
Cross-cancer analysis confirmed this pattern across 29 additional tumor types, with patients having high-risk scores consistently showing significantly worse survival outcomes. These findings highlight TIME-GES as a robust prognostic biomarker with broad applicability across diverse malignancies.
Drug Discovery Success
Using TIME-GES as a screening tool, researchers analyzed a database of 1,865 natural compounds and identified Nitidine Chloride (search) (NCD (search)) as a promising immunotherapeutic candidate. NCD ranked first at 20μM concentration and 43rd at 10μM concentration in their drug screening analysis, indicating strong and concentration-dependent modulation of TIME-GES expression.
Laboratory experiments confirmed that NCD (search) treatment upregulated the expression of key TIME-GES genes, including CXCL10 (search), CXCL11, EBI3 (search), and FLT3LG (search), in both MDA-MB-231 and 4T1 TNBC (search) cell lines. The compound exhibited moderate cytotoxicity while effectively modulating immune-related gene expression.
Mechanism of Action Revealed
Through comprehensive mechanistic studies, researchers discovered that NCD (search) exerts its immunomodulatory effects by targeting JAK2 (search) protein and inhibiting the JAK2-STAT3 (search) signaling pathway. Surface plasmon resonance analysis confirmed direct binding between NCD and JAK2 with a dissociation constant (KD) of 3.41 μM.
Western blot experiments demonstrated that NCD (search) treatment led to dose-dependent decreases in both total and phosphorylated JAK2 (search) and STAT3 (search) proteins. Gene knockdown experiments further confirmed that JAK2 inhibition upregulated the expression of the four-gene subset, establishing the mechanistic link between NCD treatment and immune gene activation.
Promising Preclinical Results
In vivo studies using a tumor-bearing mouse model demonstrated that NCD (search) treatment significantly inhibited tumor volume and weight, with high-dose treatment showing more pronounced tumor suppression. Flow cytometry analysis revealed a significant increase in CD8 (search)+ T cell infiltration in tumor tissues following NCD treatment, with a corresponding dose-dependent decline in the CD4+/CD8+ ratio.
Importantly, NCD (search) treatment showed minimal toxicity within the tested dosing range. While a modest increase in kidney index was observed at the highest dose, no abnormalities were detected in serum biochemical parameters, suggesting preserved renal and hepatic function.
Clinical Translation Potential
The research provides a strategic framework for identifying novel immunomodulatory compounds and supports the feasibility of biomarker-guided drug discovery for cancer immunotherapy. The TIME-GES approach offers several advantages over existing methods, including superior predictive performance, broad applicability across cancer types, and validation through both computational and experimental approaches.
"This work might expand therapeutic options for immunologically 'cold' tumors and supports the feasibility of biomarker-guided discovery of small molecules to potentiate cancer immunotherapy," the researchers concluded.
The study represents a significant advancement in precision immunotherapy for TNBC (search), offering both a robust biomarker for patient stratification and a novel therapeutic compound that could transform treatment outcomes for this challenging cancer subtype. Future clinical trials will be needed to validate these findings in human patients and establish the optimal integration of TIME-GES-guided therapy selection in clinical practice.